) Richard, my mother had a term (learned from HER mother) 'geshmak' to express pleasure or delight, that I will now borrow-- in a cold, and badly uninformed world, I feel utter geshmak when I read one of your knowledgeable, helpful contributions to members of this website.
What's very interesting about the first article you linked to is that it makes clear that although the biopsy is indeed carried out with MRI guidance, it is preceded by another MRI, this one a multiparametric MRI, in order to target lesions (in this study, just one lesion: the most cancerous-seeming one) to biopsy in the second MRI. And it indicates that, really, there are many ways to take advantage of the power of the mpMRI to differentiate between cancerous and normal prostate tissue. As long as you first use the mpMRI to target areas of the prostate for later biopsy, it doesn't much matter how you incorporate that information into the biopsy (thus the way they did it here, or with a fusion biopsy, which also is viewed favorably by the authors).
And the authors mentioned that this targeting allows for fewer cores to be taken without compromising the success of the mission (of course, in this context, success means finding clinically significant cancer-- something that is only pleasing in the sense that if you actually have cancer, the sooner it's found the better.)
So I say thank you, Richard, as I ride the wave of geshmak into the sunset!